He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w